Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include PARP inhibitor, Cancer research, Medicine, Oncology, RAD51, and Triple-negative breast cancer.
The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial
<i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i> -Mutant Breast Cancer
Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer